Why the study?
Does olmesartan prevent the increase in coronary atheroma volume in patients with nonsignificant coronary stenotic lesions?
Does olmesartan prevent the increase in coronary atheroma volume in patients with nonsignificant coronary stenotic lesions?
Olmesartan may have molecule-specific effects that prevent the increase in coronary atheroma volume and induce plaque stabilization.
Leaves open whether olmesartan offers unique coronary plaque benefits among ARBs; dedicated RCTs needed before clinical consideration.
Angiotensin II (Ang II) evokes inflammatory responses and plays a central role in atherosclerosis mediated by Ang II type 1 (AT1) receptor. AT1 receptor blockers (ARBs) prevent the diverse effects of Ang II. Unique molecule-specific, or off-target effects of ARBs are due to their slightly different structures, although all ARBs have common, or class, effects. In nonsignificant coronary stenotic lesions, it is important that we use aggressive medical treatments using ARBs in addition to statins and oral hypoglycemic agents, to induce the regression and stabilization of coronary plaque. This review focuses on current evidence regarding the molecule-specific effects of ARB olmesartan to prevent the increase in coronary atheroma volume.
No takes yet. Share an insight, caveat, or question.
Miura et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: